Get the Stockscreener App
17.18
2.51%
0.42
First Tracks Biotherapeutics Inc stock is traded at $17.18, with a volume of 318.54K.
It is up +2.51% in the last 24 hours and down -8.96% over the past month.
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
See More
Previous Close:
$16.76
Open:
$17.04
24h Volume:
318.54K
Relative Volume:
1.68
Market Cap:
$599.45M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+1.66%
1M Performance:
-8.96%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$16.80
$18.10
1-Week Range:
$15.40
$18.15
52-Week Range:
$15.40
$25.58
First Tracks Biotherapeutics Inc Stock (TRAX) Company Profile
Name
First Tracks Biotherapeutics Inc
Sector
Industry
Phone
212-373-3000
Address
10770 WATERIDGE CIRCLE, SAN DIEGO
Compare TRAX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRAX
First Tracks Biotherapeutics Inc
|
17.18 | 584.80M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
First Tracks Biotherapeutics Inc Stock (TRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Initiated | Leerink Partners | Outperform |
| Apr-24-26 | Initiated | Wedbush | Outperform |
| Apr-23-26 | Initiated | JP Morgan | Overweight |
| Apr-22-26 | Initiated | Barclays | Overweight |
| Apr-21-26 | Initiated | UBS | Buy |
First Tracks Biotherapeutics Inc Stock (TRAX) Latest News
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences - Sahm
Zumiez Inc. to Report Fiscal 2026 First Quarter Results - The Manila Times
First Tracks Biotherapeutics (TRAX) Stock Forecast and Price Target 2026 $TRAX - MarketBeat
TRAX Price Today: First Tracks Biotherapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
First Tracks Biotherapeutics, Inc.Ordinary Shares (NQ: TRAX - FinancialContent
AnaptysBio (ANAB) Valuation After Spin Off And Shift To Royalty Focused Model - Sahm
First Tracks Biotherapeutics (NASDAQ: TRAX) registers 10.5M resale shares; issuer gets no proceeds - Stock Titan
Emily Bodnar Reiterates Buy on AnaptysBio, Keeps $30 Price Target on ANB033 Progress and Solid Cash Runway - TipRanks
TRAX SEC FilingsFirst Tracks Biotherapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Form 424B3 First Tracks Biotherapeu - StreetInsider
First Tracks Biotherapeutics (NASDAQ: TRAX) registers 10.5M resale shares - Stock Titan
First Tracks Biotherapeutics 1Q 2026: Net loss $(50.5M), Revenue $0— 10-Q Summary - TradingView
[Form 4] First Tracks Biotherapeutics, Inc. Insider Trading Activity - Stock Titan
First Tracks Biotherapeutics (NASDAQ: TRAX) details Q1 loss and major post spin-off cash raises - Stock Titan
First Tracks Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
[8-K] First Tracks Biotherapeutics, Inc. Reports Material Event - Stock Titan
Director at First Tracks Bio (NASDAQ: TRAX) receives new equity awards - Stock Titan
Director Magda Marquet granted options and RSUs at First Tracks (TRAX) - Stock Titan
Director at First Tracks Biotherapeutics (TRAX) granted options and RSUs - Stock Titan
Director John A. Orwin receives new equity awards at First Tracks Biotherapeutics (TRAX) - Stock Titan
First Tracks (TRAX) awards director 42,000 options and 15,000 RSUs - Stock Titan
Executive equity awards at First Tracks Biotherapeutics (TRAX) detailed - Stock Titan
First Tracks (TRAX) CEO receives new stock options and RSU awards - Stock Titan
First Tracks Biotherapeutics (TRAX) CFO receives new option and RSU awards - Stock Titan
First Tracks Biotherapeutics, Inc. (TRAX) Cash From Financing (TTM) - Zacks Investment Research
First Tracks Biotherapeutics, Inc. (TRAX) Dividend (TTM) - Zacks Investment Research
This First Tracks Biotherapeutics analyst begins coverage on a bullish note; here are top 4 initiations for Monday - MSN
[EFFECT] First Tracks Biotherapeutics, Inc. SEC Filing - Stock Titan
Is AnaptysBio (ANAB) 51.9% Undervalued After Q1 2026 EPS/Revenue - GuruFocus
TRAX Should I Buy - Intellectia AI
AnaptysBio (NASDAQ: ANAB) shifts to royalty focus after Q1 2026 loss - Stock Titan
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
First Tracks Biotherapeutics, Inc. (TRAX) - Zacks Investment Research
Two new option listings and one option delisting on May 11th - TipRanks
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
First Tracks Biotherapeutics, Inc. (TRAX) Cash From Operations (TTM) - Zacks Investment Research
First Tracks Biotherapeutics, Inc. (TRAX) Net Income (TTM) - Zacks Investment Research
TRAX: First Tracks Biotherapeutics, Inc.Interactive Chart - Zacks Investment Research
First Tracks Biotherapeutics, Inc. (TRAX) Eps Diluted (TTM) - Zacks Investment Research
First Tracks Biotherapeutics, Inc. (TRAX) Ps Ratio (TTM) - Zacks Investment Research
First Tracks Biotherapeutics, Inc. (TRAX) Debt Equity Ratio (Quarterly) - Zacks Investment Research
First Tracks Biotherapeutics, Inc. (TRAX) Return On Equity (TTM) - Zacks Investment Research
First Tracks Biotherapeutics Stock Slides After Investors Move to Sell 10 Million Shares - Moomoo
Stocks to Watch: Kestrel Group, First Tracks Biotherapeutics, Inhibrx Biosciences - Moomoo
TRAX Insider Trading (First Tracks Biotherapeutics Inc stock) - StockInvest.us
First Tracks Biotherapeutics Inc Stock Data and SignalsTRAX - StockInvest.us
According to a document submitted to the U.S. Securities and Exchange Commission, existing selling shareholders of First Tracks Biotherapeutics Inc may sell up to 10.5 million shares of the company’s common stock. - Bitget
First Tracks Biotherapeuticsselling stockholders may sell up to 10.5 shares of common stockSEC filing - marketscreener.com
First Tracks Biotherapeutics, Inc. (TRAX) Dividend Yield (TTM) - Zacks Investment Research
First Tracks Biotherapeutics, Inc. (TRAX) Return On Assets (TTM) - Zacks Investment Research
First Tracks Biotherapeutics Inc Stock (TRAX) Financials Data
There is no financial data for First Tracks Biotherapeutics Inc (TRAX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):